172 related articles for article (PubMed ID: 25756670)
41. Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo: Food/herb-drug interactions and structure-activity relationships.
Bai J; Zhao S; Fan X; Chen Y; Zou X; Hu M; Wang B; Jin J; Wang X; Hu J; Zhang D; Li Y
Toxicol Appl Pharmacol; 2019 Apr; 369():49-59. PubMed ID: 30790579
[TBL] [Abstract][Full Text] [Related]
42. Structure-activity relationships of the inhibitory effects of flavonoids on P-glycoprotein-mediated transport in KB-C2 cells.
Kitagawa S; Nabekura T; Takahashi T; Nakamura Y; Sakamoto H; Tano H; Hirai M; Tsukahara G
Biol Pharm Bull; 2005 Dec; 28(12):2274-8. PubMed ID: 16327165
[TBL] [Abstract][Full Text] [Related]
43. Synthesis, biological evaluation and 3D-QSAR studies of new chalcone derivatives as inhibitors of human P-glycoprotein.
Parveen Z; Brunhofer G; Jabeen I; Erker T; Chiba P; Ecker GF
Bioorg Med Chem; 2014 Apr; 22(7):2311-9. PubMed ID: 24613626
[TBL] [Abstract][Full Text] [Related]
44. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
[TBL] [Abstract][Full Text] [Related]
45. Indoloquinoxaline compounds that selectively antagonize P-glycoprotein.
Smith CD; Myers CB; Zilfou JT; Smith SN; Lawrence DS
Oncol Res; 2000; 12(5):219-29. PubMed ID: 11417747
[TBL] [Abstract][Full Text] [Related]
46. Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells.
Fong WF; Shen XL; Globisch C; Wiese M; Chen GY; Zhu GY; Yu ZL; Tse AK; Hu YJ
Bioorg Med Chem; 2008 Apr; 16(7):3694-703. PubMed ID: 18313307
[TBL] [Abstract][Full Text] [Related]
47. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein.
Shepard RL; Winter MA; Hsaio SC; Pearce HL; Beck WT; Dantzig AH
Biochem Pharmacol; 1998 Sep; 56(6):719-27. PubMed ID: 9751076
[TBL] [Abstract][Full Text] [Related]
48. Simple purification of highly active biotinylated P-glycoprotein: enantiomer-specific modulation of drug-stimulated ATPase activity.
Julien M; Kajiji S; Kaback RH; Gros P
Biochemistry; 2000 Jan; 39(1):75-85. PubMed ID: 10625481
[TBL] [Abstract][Full Text] [Related]
49. Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter.
Tiberghien F; Kurome T; Takesako K; Didier A; Wenandy T; Loor F
J Med Chem; 2000 Jun; 43(13):2547-56. PubMed ID: 10891114
[TBL] [Abstract][Full Text] [Related]
50. P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistance-associated protein (MRP) expression in acute promyelocytic leukaemia.
Michieli M; Damiani D; Ermacora A; Geromin A; Michelutti A; Masolini P; Baccarani M
Br J Haematol; 2000 Mar; 108(4):703-9. PubMed ID: 10792272
[TBL] [Abstract][Full Text] [Related]
51. Correlation between the affinity of flavonoids binding to the cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin.
Pérez-Victoria JM; Chiquero MJ; Conseil G; Dayan G; Di Pietro A; Barron D; Castanys S; Gamarro F
Biochemistry; 1999 Feb; 38(6):1736-43. PubMed ID: 10026252
[TBL] [Abstract][Full Text] [Related]
52. 2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein.
Jabeen I; Wetwitayaklung P; Chiba P; Pastor M; Ecker GF
J Comput Aided Mol Des; 2013 Feb; 27(2):161-71. PubMed ID: 23400406
[TBL] [Abstract][Full Text] [Related]
53. The interaction of flavonoid-lysozyme and the relationship between molecular structure of flavonoids and their binding activity to lysozyme.
Yang R; Yu L; Zeng H; Liang R; Chen X; Qu L
J Fluoresc; 2012 Nov; 22(6):1449-59. PubMed ID: 22772804
[TBL] [Abstract][Full Text] [Related]
54. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.
Breier A; Barancík M; Sulová Z; Uhrík B
Curr Cancer Drug Targets; 2005 Sep; 5(6):457-68. PubMed ID: 16178819
[TBL] [Abstract][Full Text] [Related]
55. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein.
Sauna ZE; Ambudkar SV
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2515-20. PubMed ID: 10716986
[TBL] [Abstract][Full Text] [Related]
56. Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein.
Ruth A; Stein WD; Rose E; Roninson IB
Biochemistry; 2001 Apr; 40(14):4332-9. PubMed ID: 11284689
[TBL] [Abstract][Full Text] [Related]
57. The structure and functions of P-glycoprotein.
Li Y; Yuan H; Yang K; Xu W; Tang W; Li X
Curr Med Chem; 2010; 17(8):786-800. PubMed ID: 20088754
[TBL] [Abstract][Full Text] [Related]
58. MDR1/P-glycoprotein expression in colorectal cancer.
Linn SC; Giaccone G
Eur J Cancer; 1995; 31A(7-8):1291-4. PubMed ID: 7577038
[TBL] [Abstract][Full Text] [Related]
59. P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake.
de Graaf D; Sharma RC; Mechetner EB; Schimke RT; Roninson IB
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1238-42. PubMed ID: 8577747
[TBL] [Abstract][Full Text] [Related]
60. Visualization of multidrug resistance in vivo.
Hendrikse NH; Franssen EJ; van der Graaf WT; Vaalburg W; de Vries EG
Eur J Nucl Med; 1999 Mar; 26(3):283-93. PubMed ID: 10079321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
